Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 330

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer

Open access
Sequist, Lecia V., Gettinger, Scott, Senzer, Neil N., Martins, Renato G., Jänne, Pasi A., Lilenbaum, Rogerio, Gray, Jhanelle E., Iafrate, A. John, Katayama, Ryohei, Hafeez, Nafeeza, Sweeney, Jennifer, Walker, John R., Fritz, Christian, Ross, Robert W., Grayzel, David, Engelman, Jeffrey A., Borger, Darrell R., Paez, Guillermo, Natale, Ronald·2010·Journal of Clinical Oncology

Abstract

Purpose: IPI-504 is a novel, water-soluble, potent inhibitor of heat-shock protein 90 (Hsp90). Its potential anticancer activity has been validated in preclinical in vitro and in vivo models. We studied the activity of IPI-504 after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced, molecularly defined non–small-cell lung cancer (NSCLC). Patients and Methods: Patients with advanced NSCLC, prior treatment with EGFR TKIs, and tumor tissue available for molecular genotyping were enrolled in this prospective, nonrandomized, multicenter, phase II study of IPI-504 monotherapy. The primary outcome was objective response rate (ORR). Secondary aims included safety, progression-free survival (PFS), and analysis of activity by molecular subtypes. Results: Seventy-six patients were enrolled between December 2007 and May 2009 from 10 United States cancer centers. An ORR of 7% (five of 76) was observed in the overall study population, 10% (four of 40) in patients who were EGFR wild-type, and 4% (one of 28) in those with EGFR mutations. Although both EGFR groups were below the target ORR of 20%, among the three patients with an ALK gene rearrangement, two had partial responses and the third had prolonged stable disease (7.2 months, 24% reduction in tumor size). The most common adverse events included grades 1 and 2 fatigue, nausea, and diarrhea. Grade 3 or higher liver function abnormalities were observed in nine patients (11.8%). Conclusion: IPI-504 has clinical activity in patients with NSCLC, particularly among patients with ALK rearrangements.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2010.30.8338

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 330

Metadata

Authors
Sequist, L. V., Gettinger, S., Senzer, N. N., Martins, R. G., Jänne, P. A., Lilenbaum, R., Gray, J. E., Iafrate, A. J., Katayama, R., Hafeez, N., Sweeney, J., Walker, J. R., Fritz, C., Ross, R. W., Grayzel, D., Engelman, J. A., Borger, D. R., Paez, G., & Natale, R.
Venue
Journal of Clinical Oncology
Published
2010-11-20
Volume
28
Issue
33
Pages
4953-4960
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2114032749
Cited by
330
References
10
FWCI
31.98
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer. https://app.cochat.ai/papers/10.1200/jco.2010.30.8338
The paper
Sequist, L. V., Gettinger, S., Senzer, N. N., Martins, R. G., Jänne, P. A., Lilenbaum, R., Gray, J. E., Iafrate, A. J., Katayama, R., Hafeez, N., Sweeney, J., Walker, J. R., Fritz, C., Ross, R. W., Grayzel, D., Engelman, J. A., Borger, D. R., Paez, G., & Natale, R. (2010). Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2010.30.8338

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.